Biopharma industry experts gather in Singapore to discuss strategy, investment, innovation and partnership opportunities in Asia
BioPharma Asia Convention 2012
19 – 22 March 2012
Marina Bay Sands, Singapore
www.terrapinn.com/biopharma
Singapore, 15 March 2012 – Come 19 - 22 March 2012, the annual BioPharma Asia Convention 2012 will take centre stage, providing a platform for the biopharma industry to find the right partners for their business needs at Marina Bay Sands, Singapore.
Anders Ekblom, Executive Vice President, Science and Technology, AstraZeneca, Sweden
•
Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery, Bayer HealthCare, Germany
•
Anand Tharmaratham, Senior Vice President and Head of Asia Markets, Clinical Development, Quintiles, Singapore
•
Chihiro Yokota, Corporate Executive, Global Head of Business Development/Licensing & Alliances, Astellas Pharma, Japan
•
Saloman Azoulay, Senior Vice President, Medical and Development, Emerging Markets/Established Products Business Units, Pfizer, USA
•
Greg Guyer, Senior Vice President, Global Quality, Merck, USA
•
Paul Coleman, Chief Executive Officer, Bio Business Unit, Hanwha Chemical, Korea
•
Atushi Nagahisa, President & Chief Executive Officer, RaQualia, Japan
•
Yuan Xu, Vice President and Head of Biotherapuetics, Novartis, USA
•
Bob Elliot, Medical Director, Living Cell Technologies, New Zealand
•
•
Kiran Mazumdar Shaw, Chairman & Managing Director, Biocon, India